Company: TELO
Filing Date: 2025-09-18
Form Type: 8-K
Source: 0001493152-25-013970
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-09-18
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals AnnouncesIn VitroData Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in
Cancer and Aging Not Seen in Other Therapies

New
in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially
representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth.

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO) today announced new in vitro

In
cancer and aging, the silencing of protective genes occurs through two major mechanisms. First, histone demethylases act as switches:
proteins of the KDM5 family erase activation marks from tumor suppressor genes and remove repressive marks from genes that drive proliferation
and inflammation. Together, these enzymes disable cell-protective pathways and enhance harmful ones. Second, DNA methylation then reinforces
the silencing by adding chemical tags to gene promoters, locking tumor suppressors in an inactive state making the silence durable and
heritable as cells divide.

In
the new in vitro

In
addition to these findings, Telomir-1 has previously demonstrated activity across other families of histone demethylases, including UTX
(KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A). These enzymes are associated with cancer progression, stemness, immune evasion,
and age-related decline. Telomir-1 was also shown to spare broad acetyltransferases such as GCN5L2, which are associated with systemic
toxicity when inhibited.

In
other previously reported in vivo

Taken
together, these results indicate that Telomir-1 has demonstrated broad-spectrum activity across both DNA methylation and several histone
demethylation pathways, the two fundamental axes of epigenetic control. The company continues to advance IND-enabling studies and GMP
scale-up of Telomir-1, with additional preclinical evaluations ongoing across aggressive cancers and models of aging.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                          TELOMIR